BeOne Medicines AG (BVMF:B1ME34)
Brazil
· Delayed Price · Currency is BRL 67.22
0.00 (0.00%)
At close: Mar 4, 2026
BeOne Medicines AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 5,282 | 3,780 | 2,190 | 1,416 | 1,176 | Upgrade
|
| Other Revenue | 60.97 | 30.7 | 268.93 | - | - | Upgrade
|
| Revenue | 5,343 | 3,810 | 2,459 | 1,416 | 1,176 | Upgrade
|
| Revenue Growth (YoY) | 40.23% | 54.96% | 73.65% | 20.37% | 280.83% | Upgrade
|
| Cost of Revenue | 668.54 | 594.09 | 379.92 | 286.48 | 164.91 | Upgrade
|
| Gross Profit | 4,674 | 3,216 | 2,079 | 1,129 | 1,011 | Upgrade
|
| Selling, General & Admin | 2,081 | 1,831 | 1,508 | 1,279 | 990.12 | Upgrade
|
| Research & Development | 2,146 | 1,953 | 1,779 | 1,641 | 1,459 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | - | 0.75 | Upgrade
|
| Operating Expenses | 4,227 | 3,784 | 3,287 | 2,919 | 2,450 | Upgrade
|
| Operating Income | 447.14 | -568.2 | -1,208 | -1,790 | -1,439 | Upgrade
|
| Interest Expense | -58.23 | -21.81 | -4.36 | -19.11 | -28.21 | Upgrade
|
| Interest & Investment Income | 70.51 | 69.64 | 78.37 | 71.59 | 12.45 | Upgrade
|
| Earnings From Equity Investments | -14.98 | -10.28 | -7.86 | -3.68 | -1.8 | Upgrade
|
| Other Non Operating Income (Expenses) | 31.96 | 6.54 | -40.3 | -195.13 | 8.31 | Upgrade
|
| EBT Excluding Unusual Items | 476.39 | -524.1 | -1,182 | -1,936 | -1,448 | Upgrade
|
| Gain (Loss) on Sale of Investments | -59.53 | -8.9 | -6.87 | -25.04 | 9.39 | Upgrade
|
| Other Unusual Items | - | - | 362.92 | - | - | Upgrade
|
| Pretax Income | 416.85 | -533 | -825.84 | -1,961 | -1,439 | Upgrade
|
| Income Tax Expense | 129.92 | 111.79 | 55.87 | 42.78 | 19.23 | Upgrade
|
| Earnings From Continuing Operations | 286.93 | -644.79 | -881.71 | -2,004 | -1,458 | Upgrade
|
| Net Income | 286.93 | -644.79 | -881.71 | -2,004 | -1,458 | Upgrade
|
| Net Income to Common | 286.93 | -644.79 | -881.71 | -2,004 | -1,458 | Upgrade
|
| Shares Outstanding (Basic) | 109 | 105 | 104 | 103 | 93 | Upgrade
|
| Shares Outstanding (Diluted) | 113 | 105 | 104 | 103 | 93 | Upgrade
|
| Shares Change (YoY) | 7.75% | 0.86% | 1.22% | 11.15% | 11.16% | Upgrade
|
| EPS (Basic) | 2.63 | -6.12 | -8.45 | -19.43 | -15.71 | Upgrade
|
| EPS (Diluted) | 2.47 | -6.12 | -8.45 | -19.43 | -15.71 | Upgrade
|
| Free Cash Flow | 941.74 | -633.29 | -1,719 | -1,822 | -1,562 | Upgrade
|
| Free Cash Flow Per Share | 8.30 | -6.01 | -16.47 | -17.67 | -16.83 | Upgrade
|
| Gross Margin | 87.49% | 84.41% | 84.55% | 79.77% | 85.98% | Upgrade
|
| Operating Margin | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% | Upgrade
|
| Profit Margin | 5.37% | -16.92% | -35.86% | -141.52% | -123.93% | Upgrade
|
| Free Cash Flow Margin | 17.63% | -16.62% | -69.93% | -128.68% | -132.76% | Upgrade
|
| EBITDA | 578.82 | -401.17 | -1,124 | -1,727 | -1,393 | Upgrade
|
| EBITDA Margin | 10.83% | -10.53% | -45.71% | -121.94% | -118.44% | Upgrade
|
| D&A For EBITDA | 131.68 | 167.03 | 83.94 | 63.05 | 45.49 | Upgrade
|
| EBIT | 447.14 | -568.2 | -1,208 | -1,790 | -1,439 | Upgrade
|
| EBIT Margin | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% | Upgrade
|
| Effective Tax Rate | 31.17% | - | - | - | - | Upgrade
|
| Revenue as Reported | 5,343 | 3,810 | 2,459 | 1,416 | 1,176 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.